Medicine
Epysqli 300 mg/30 mL injection
Epysqli 300 mg/30 mL injection is a prescription medicine containing Eculizumab for intravenous use, marketed by Teva Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store EPYSQLI vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the…
Key facts
- Active ingredient (INN)
- Eculizumab
- Brand
- Epysqli
- Strength
- 300 mg/30 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 30 mL
- Marketing authorisation holder
- Teva Pharmaceuticals
- Manufacturer
- Teva Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store EPYSQLI vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use. DO NOT FREEZE. Prior to administration, if needed, unopened vials of EPYSQLI may be stored in the original carton at controlled room temperature [not more than 30°C (86°F)] for a single 1 month period and then returned to refrigeration for 3 days. DO NOT SHAKE.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AJ01 Eculizumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 7 April 2025
- Identifiers
- RxCUI 2706338, 2706345DailyMed set ID 1fa1aa80-1c59-44d4-9841-b6c52882651bNDC 51759-208Application BLA761340
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 30 mL in 1 vial, single-dose | 51759-208-13 | Teva Pharmaceuticals | 7 April 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Eculizumab 300 mg/30 mL injection.
Clinical summary
Eculizumab is a complement inhibitor indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Eculizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about EculizumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- SOLIRIS prescribing information (Alexion Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Soliris: European public assessment report (EPAR) · European Medicines Agency
- Bekemv: European public assessment report (EPAR) · European Medicines Agency
Need Epysqli 300 mg/30 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.